EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

Anti-Human Epidermal Growth Factor Receptor-2 Therapies in Biliary Tract Cancers: A Meta-Analysis on Disease Location, Human Epidermal Growth Factor Receptor-2 Status, and Survival Outcomes

Silvia Camera, Margherita Rimini, Silvia Foti, Federica Lo Prinzi, Francesco Vitiello, Elisabeth Amadeo, Mara Persano, Stefano Cascinu, Andrea Casadei-Gardini, Federico Rossari

Oncology · 26.05.2025 · 104 (3) · 306-318

DOI: 10.1159/000545308 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Oncology, online erschienen am 26.05.2025. Verfasst von Silvia Camera und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Biliary Tract Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 61 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

In recent years, the therapeutic scenario of metastatic biliary tract cancers (BTCs) beyond first-line has profoundly changed owing to target therapies. human epidermal growth factor receptor-2 (HER2) represents a promising molecular target that is frequently altered in BTC. The present meta-analyses aimed to describe the response rates and survival outcomes in patients with HER2-positive locally advanced/metastatic BTC treated with anti-HER2 therapies. Moreover, the study is intended to provide an update on the evolving therapeutic scenario of HER2-overexpressed BTC.

Methods

We performed a systematic review of the literature to identify clinical trials investigating any regimen comprising a HER2-targeted therapy for metastatic BTC, and we conducted three subsequent meta-analyses on second-line phase II trials. The first one was performed to compare the group of HER2 3+ versus the group of HER2 2+ BTC patients for objective response rate (ORR). The second one compared patients according to the tumor location (gallbladder carcinoma [GBC] or extrahepatic cholangiocarcinoma [eCCA] versus intrahepatic cholangiocarcinoma [iCCA]) for ORR. The third one evaluated the overall outcomes in terms of overall survival (OS) and progression-free survival (PFS).

Results

Patients with advanced BTC and HER2 3+ had better ORR compared to HER2 2+, with a 3.7-fold higher probability of experiencing objective responses (HR 3.70, 95% CI, 1.34–10.25, p = 0.0119). Likewise, patients with GBC or eCCA had a 2.74-fold higher probability of experiencing an objective response compared to patients with iCCA (HR 2.74, 95% CI, 1.12–6.73, p = 0.0275). The weighted pooled analysis of trials with anti-HER2 agents in second line or beyond revealed an mPFS of 4.9 months (95% CI, 4.2–5.6), while mOS was 10.8 months (95% CI, 9.0–12.8).

Conclusions

Our meta-analyses have revealed improved efficacy in patients with HER2 3+ metastatic BTC and in patients with GBC or eCCA treated with anti-HER2 therapies, with a considerable mPFS and mOS in the overall population of the phase II trials analyzed. Further studies are paramount to confirm our preliminary results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesBiliary Tract NeoplasmsHumansClinical Trials, Phase II as TopicTreatment OutcomeMolecular Targeted Therapy

Stichwörter der Autor:innen

Anti-human epidermal growth factor receptor-2 therapiesBiliary tract cancerHuman epidermal growth factor receptor-2

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, human

Autor:innen und Institutionen

  • Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.
  • Operative Research Unit of Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
  • Medical Oncology, University and University Hospital of Cagliari, Cagliari, Italy.
  • Department of Oncology, Vita-Salute San Raffaele University, IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy, casadeigardini@gmail.com.
  • San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), IRCCS San Raffaele Scientific Institute Hospital, Milan, Italy.

Zitieren

APA

Camera, S., Rimini, M., Foti, S., Lo Prinzi, F., Vitiello, F., Amadeo, E., Persano, M., Cascinu, S., Casadei-Gardini, A., & Rossari, F. (2025). Anti-Human Epidermal Growth Factor Receptor-2 Therapies in Biliary Tract Cancers: A Meta-Analysis on Disease Location, Human Epidermal Growth Factor Receptor-2 Status, and Survival Outcomes. Oncology, 104(3), 306-318. https://doi.org/10.1159/000545308

Vancouver

Camera S, Rimini M, Foti S, Lo Prinzi F, Vitiello F, Amadeo E, et al. Anti-Human Epidermal Growth Factor Receptor-2 Therapies in Biliary Tract Cancers: A Meta-Analysis on Disease Location, Human Epidermal Growth Factor Receptor-2 Status, and Survival Outcomes. Oncology. 2025;104(3):306-318. doi:10.1159/000545308

BibTeX
@article{Camera2025,
  author = {Camera, Silvia and Rimini, Margherita and Foti, Silvia and Lo Prinzi, Federica and Vitiello, Francesco and Amadeo, Elisabeth and Persano, Mara and Cascinu, Stefano and Casadei-Gardini, Andrea and Rossari, Federico},
  title = {Anti-Human Epidermal Growth Factor Receptor-2 Therapies in Biliary Tract Cancers: A Meta-Analysis on Disease Location, Human Epidermal Growth Factor Receptor-2 Status, and Survival Outcomes},
  journal = {Oncology},
  year = {2025},
  volume = {104},
  number = {3},
  pages = {306--318},
  doi = {10.1159/000545308}
}
Kostenlos starten →